● Recruiting

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Condition: Breast Cancer · Adjuvant Therapy · Sponsor: Fudan University

PhasePhase 3

Planned participants1903

Who can joinFemale, 18 Years to 70 Years

Healthy volunteersNo

About this study

This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Building upon anti-HER2 targeted therapy combined with endocrine therapy, the addition of CDK4/6 inhibitors has demonstrated greater clinical benefits for advanced TPBC patients. This study aims to investigate the efficacy and safety of CDK4/6 inhibitor combination with standard adjuvant endocrine therapy in HR+/HER2+ early breast cancer patients.

This description comes directly from the study's public registry record.

Talk to the study team

Zhimin Shao, MD, PhD · +86-021-64175590 · zhi_ming_shao@163.com

min he · zhi_ming_shao@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan cancer center

Shanghai, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07019363